AIBS joined 55 other organizations in sending a letter to appropriators requesting at least $7.29 billion for the National Institute of Allergy and Infectious Diseases (NIAID) and at least $51.303 billion for the National Institutes of Health (NIH) overall for fiscal year (FY) 2026, representing a 9% increase over FY 2025 levels.
The letter reads in part:
NIAID plays an essential role in addressing influenza, asthma, cancer, HIV/AIDS, sepsis, deadly allergic reactions, immunodeficiencies, autoimmune disorders, tuberculosis, malaria and other vector-borne diseases, neglected diseases, lupus and so much more. With a unique mandate to better understand, treat, and prevent infectious, immunologic, and allergic diseases, NIAID has consistently forged paths to improve health and save lives. NIAID’s cutting-edge research and network of scientists are eliminating some of the world’s most serious health threats, as well as addressing risks to national security and public health, including antimicrobial resistance (AMR). NIAID researchers also uncover the links between infectious diseases and chronic conditions, which can be triggered by an infection; these discoveries lead to the development of countermeasures to protect individuals with chronic illnesses, who are more susceptible to infections. By staying at the forefront of research, NIAID-funded scientists and clinicians protect American lives and prevent instability that could impact U.S. economic and national interests.
Stay current on the latest science policy news. Subscribe to our bi-weekly AIBS Public Policy Report.